FDA's Challenge To Implied Outcomes Of ADHD Drugs
In Warning Letters to two companies, and in Untitled Letters to three, the U.S. Food and Drug Administration's (FDA's) Division of Drug Marketing, Advertising, and Communications (DDMAC) on Sep. 25, 2008,...To view the full article, register now.
Already a subscriber? Click here to view full article